Lifeward Ltd SEC Filings

Lifeward Ltd. furnished a press release announcing its financial results for the second quarter ended June 30, 2025. The company will host a conference call to discuss those results at 8:30 a.m. E.D.T. on August 14, 2025, and an archived webcast will be available at the provided link and on the company’s Investors page for 30 days. The press release is furnished as Exhibit 99.1 and the cover page interactive XBRL is provided as Exhibit 104. The filing states these materials are furnished and are not to be deemed “filed” or incorporated by reference into other securities filings. The company’s ordinary shares trade under the LFWD ticker on the Nasdaq Capital Market.

Adar Almog, identified on the form as the company’s Chief Financial Officer, received a grant of stock options under the 2025 Incentive Compensation Plan. The award covers 225,000 options with an exercise price of $0.717 per share and was recorded with a transaction date of 08/13/2025. The options vest in four equal annual installments beginning 08/13/2026 and expire on 08/13/2035, and are reported as a direct holding tied to 225,000 ordinary shares (par value NIS 1.75). The form states a price of the derivative security of $0 and notes vesting is subject to continued service.

Lifeward Ltd. appointed Almog Adar as its Chief Financial Officer, effective August 1, 2025. Mr. Adar, age 42, is an internal promotion from Vice President of Finance and Chief Accounting Officer and will continue as the company’s principal accounting officer.

His compensation package includes an annual base salary of $315,000, an annual performance bonus opportunity of up to 35% of base salary, a one-time retention payment of $80,000 (paid in two installments), eligibility for an additional prorated 7% bonus for 2025, and a grant of options to purchase 225,000 ordinary shares vesting in four equal annual installments. Termination protections include six months salary continuation (longer for a change of control), target bonus continuation, health premium reimbursement, and accelerated vesting on certain change-of-control terminations. The agreement includes non-solicitation, non-competition and indemnification provisions.

Lifeward Ltd. received a notification from The Nasdaq Stock Market that its closing bid price has been below the required minimum of $1.00 per share for the last 30 consecutive business days. The notice is a deficiency, not a delisting, and does not currently affect the listing or trading of the companys ordinary shares.

The company has 180 days to regain compliance, until February 2, 2026, by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Lifeward may be eligible for a second 180-day cure period if, as of that date, it has a market value of publicly held shares of at least $1 million, meets other initial listing standards except the bid price requirement, and provides written notice of its intent to cure.

Management states it will monitor the closing bid price and consider plans to regain compliance but expressly warns there is no assurance it will be able to do so within the cure period or any extension. The report includes customary forward-looking statements and refers readers to the companys SEC filings for additional risk factors.

Form 4 filing for Lifeward Ltd. (LFWD) discloses one routine equity award to non-executive director Randel Richner.

• Transaction: On 01-Aug-2025 the director received 35,920 restricted stock units (RSUs) of ordinary shares (par NIS 1.75) at $0 cost.
• Vesting schedule: RSUs vest in four equal quarterly instalments beginning three months after the grant date.
• Post-grant holdings: Richner now indirectly owns 57,487 shares through the company ESOP.
• No derivative securities, sales, or open-market purchases were reported.

The filing reflects standard board compensation intended to align director interests with shareholders. The modest share count suggests immaterial dilution at the company level and no immediate cash impact.

Form 4 filing for Lifeward Ltd. (LFWD) discloses the first reportable transaction by director Hadar Levy on 1 Aug 2025.

• Transaction: Acquisition of 35,920 ordinary shares via restricted stock units (RSUs) granted under the 2025 Incentive Compensation Plan. The award was booked at $0.00 cost, indicating a compensation grant rather than a market purchase.
• Vesting terms: RSUs vest in four equal quarterly tranches beginning three months after the grant date.
• Post-transaction ownership: Levy now holds 51,576 shares indirectly through the company ESOP.
• The reported share balances already reflect Lifeward’s 1-for-7 reverse share split effective 15 Mar 2024.

No derivative securities or sales were reported. The filing shows additional equity alignment for a board member but does not involve cash outlay or immediate market activity, so short-term dilution and trading-signal effects are minimal.

Form 4 snapshot for Lifeward Ltd. (LFWD): On 08/01/2025 director Joseph E. Turk Jr. received 71,839 restricted stock units (RSUs) under the 2025 Incentive Compensation Plan. The award carries no cash consideration (price $0.00) and will vest in four equal quarterly tranches beginning three months after the grant date.

The filing also shows a disposition of 18,516 ordinary shares and reports total indirect beneficial ownership of 86,457 ordinary shares held through the company ESOP following the transactions. No derivative securities were involved.

Because the RSUs are an equity-based incentive, cash flow is unaffected; any dilution impact is minimal relative to Lifeward’s outstanding share count (not disclosed in the filing). The transaction signals continued board-level alignment with shareholders but does not, by itself, alter the firm’s fundamentals or outlook.